← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Alpha Cognition Inc. Common Stock (ACOG) 10-Year Financial Performance & Capital Metrics

ACOG • • Banking & Credit
Financial ServicesFinancial ConglomeratesHealthcare & Biotech HoldingsBiopharmaceutical Development
AboutAlpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.Show more
  • Net Interest Income -$24K +60.4%
  • Total Revenue $0
  • Net Income -$15M -6.3%
  • Return on Equity -79.66%
  • Net Interest Margin -0.05% +98.1%
  • Efficiency Ratio -
  • ROA -55.04% +89.2%
  • Equity / Assets 81.72% +142.5%
  • Book Value per Share 5.72 +535.2%
  • Tangible BV/Share 5.66 +487.2%
  • Debt/Equity 0.02
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Well capitalized: 81.7% equity/assets
  • ✓Trading at only 1.0x book value

✗Weaknesses

  • ✗Weak NIM of -0.0%
  • ✗Weak momentum: RS Rating 16 (bottom 16%)
  • ✗Shares diluted 100.0% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-
TTM-

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-31.83%

EPS CAGR

10Y-
5Y-
3Y-
TTM44.46%

ROCE

10Y Avg-145.73%
5Y Avg-145.73%
3Y Avg-160.16%
Latest-50.24%

Peer Comparison

Biopharmaceutical Development
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
ACOGAlpha Cognition Inc. Common Stock126.54M5.82-2.88-57.42%0.02

Profit & Loss

Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Net Interest Income+-747.78K-526.09K-170.96K-60.91K-24.11K
NII Growth %-0.3%0.68%0.64%0.6%
Net Interest Margin %-----
Interest Income22.59K2.07K1.93K6.8K161.66K
Interest Expense770.37K528.16K172.88K67.71K185.78K
Loan Loss Provision-770.37K-528.16K-172.88K-67.71K-185.78K
Non-Interest Income+-22.59K-2.07K-1.93K-6.8K-161.66K
Non-Interest Income %-----
Total Revenue+00000
Revenue Growth %-----
Non-Interest Expense5.71M11.57M13.47M9.62M11.86M
Efficiency Ratio-----
Operating Income+-5.71M-11.57M-13.47M-9.62M-11.86M
Operating Margin %-----
Operating Income Growth %--1.03%-0.16%0.29%-0.23%
Pretax Income+-5.78M-19.55M-12.11M-13.77M-14.64M
Pretax Margin %-----
Income Tax+00000
Effective Tax Rate %-----
Net Income+-5.78M-19.55M-12.11M-13.77M-14.64M
Net Margin %-----
Net Income Growth %--2.38%0.38%-0.14%-0.06%
Net Income (Continuing)-5.78M-19.55M-12.11M-13.77M-14.64M
EPS (Diluted)+-2.79-9.25-4.50-3.84-2.02
EPS Growth %--2.32%0.51%0.15%0.47%
EPS (Basic)-2.79-9.25-4.50-3.84-2.02
Diluted Shares Outstanding2.07M2.13M2.72M3.59M7.25M

Balance Sheet

Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash & Short Term Investments+1000K1000K1000K1000K1000K
Cash & Due from Banks5.93M11.3M2.08M1.49M48.55M
Short Term Investments00000
Total Investments+00000
Investments Growth %-----
Long-Term Investments00000
Accounts Receivables00000
Goodwill & Intangibles+-----
Goodwill00000
Intangible Assets729.14K696.76K614.39K532.01K412.97K
PP&E (Net)6.84K13K3.82K1.72K27.08K
Other Assets000045.71K
Total Current Assets7.7M12.17M2.33M1.92M50.25M
Total Non-Current Assets735.97K709.76K618.21K533.73K485.76K
Total Assets+8.44M12.88M2.95M2.45M50.74M
Asset Growth %-0.53%-0.77%-0.17%19.69%
Return on Assets (ROA)-0.69%-1.83%-1.53%-5.1%-0.55%
Accounts Payable27.54K454.99K2.02M0872.68K
Total Debt+3.22M1.08M1.21M1.22M911.46K
Net Debt-2.71M-10.23M-872.23K-274.2K-47.63M
Long-Term Debt3.19M0000
Short-Term Debt24K1.08M1.21M1.22M911.46K
Other Liabilities1.65M2.05M214.28K4.54M5.92M
Total Current Liabilities3.58M1.8M4.06M2.62M3.35M
Total Non-Current Liabilities4.84M2.05M214.28K4.54M5.92M
Total Liabilities8.42M3.85M4.27M7.16M9.27M
Total Equity+16.01K9.03M-1.32M-4.71M41.46M
Equity Growth %-563.07%-1.15%-2.57%9.8%
Equity / Assets (Capital Ratio)-----
Return on Equity (ROE)-361.33%-4.32%-3.14%--0.8%
Book Value per Share0.014.23-0.49-1.315.72
Tangible BV per Share-----
Common Stock14.57M40.01M40.26M50.35M99.13M
Additional Paid-in Capital000018.72M
Retained Earnings-18.49M-38.03M-49.99M-63.35M-76.29M
Accumulated OCI3.94M7.05M8.41M8.29M-104.3K
Treasury Stock00000
Preferred Stock0620062

Cash Flow

Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-5.44M-9.88M-9.24M-8.73M-7.76M
Operating CF Growth %--0.82%0.06%0.06%0.11%
Net Income-5.78M-19.55M-12.11M-13.77M-14.64M
Depreciation & Amortization81.44K89.88K90.92K84.48K81.22K
Deferred Taxes00000
Other Non-Cash Items36.01K8.07M-1.65M4.15M6.06M
Working Capital Changes-325.82K-288.96K2.73M-1.56M-241.68K
Cash from Investing+-9.24K459.38K-4.88K0-26.7K
Purchase of Investments00000
Sale/Maturity of Investments00000
Net Investment Activity-----
Acquisitions0523.04K000
Other Investing0-50K000
Cash from Financing+5.88M14.88M24.79K8.16M54.85M
Dividends Paid00000
Share Repurchases00000
Stock Issued1.9M13.65M09.22M56.54M
Net Stock Activity-----
Debt Issuance (Net)1000K-24K0-55K1000K
Other Financing-23K1.23M24.79K-1.01M-5.93M
Net Change in Cash+428.84K5.38M-9.22M-589.12K47.07M
Exchange Rate Effect0-82.84K3.64K-19.57K0
Cash at Beginning5.5M5.93M11.3M2.08M1.49M
Cash at End5.93M11.3M2.08M1.49M48.56M
Interest Paid0016K59.78K37.75K
Income Taxes Paid00000
Free Cash Flow+-5.45M-9.94M-9.25M-8.73M-7.78M
FCF Growth %--0.83%0.07%0.06%0.11%

Banking Ratios

Metric20202021202220232024
Return on Equity (ROE)-36133.23%-432.14%-314.28%--79.66%
Return on Assets (ROA)-68.56%-183.38%-153.05%-509.8%-55.04%
Net Interest Margin-8.86%-4.08%-5.79%-2.48%-0.05%
Equity / Assets0.19%70.1%-44.74%-192.18%81.72%
Book Value / Share0.014.23-0.49-1.315.72
NII Growth-29.65%67.5%64.37%60.41%

Frequently Asked Questions

Growth & Financials

Alpha Cognition Inc. Common Stock (ACOG) grew revenue by 0.0% over the past year. Growth has been modest.

Alpha Cognition Inc. Common Stock (ACOG) reported a net loss of $19.5M for fiscal year 2024.

Dividend & Returns

Alpha Cognition Inc. Common Stock (ACOG) has a return on equity (ROE) of -79.7%. Negative ROE indicates the company is unprofitable.

Industry Metrics

Alpha Cognition Inc. Common Stock (ACOG) has a net interest margin (NIM) of -0.0%. NIM has been under pressure due to interest rate environment.

Alpha Cognition Inc. Common Stock (ACOG) has an efficiency ratio of 0.0%. This is excellent, indicating strong cost control.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.